Please ensure Javascript is enabled for purposes of website accessibility

Why Sangamo Therapeutics Rocketed Higher Today

By Brian Orelli, PhD - Updated Feb 22, 2018 at 11:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The gene editing company scores another deal.

What happened

Sangamo Therapeutics (SGMO -1.37%) is up 20% at 11:43 a.m. EST after announcing a collaboration with Kite, which was acquired by Gilead Sciences (GILD 0.80%) last year. The duo plans to use Sangamo's zinc finger nuclease technology to edit DNA to develop cell therapies to treat cancer, which is Kite's specialty.

So what

Kite's current treatments -- chimeric antigen receptor (CAR) and T cell receptor (TCR)-engineered cell therapies -- take immune cells from patients, train the T cells using CAR or TCR to attack the cancerous cells, and then reintroduce the cells to the patient. Since the cells are from the same patient, it's considered an "autologous" therapy.

A female technician in a lab coat standing over a seated male patient and preparing him for an infusion

Image source: Getty Images.

Sangamo and Kite are hoping to develop "allogeneic" cell therapies that are made from healthy donor cells or from renewable stem cells. The treatments could be premade and available for infusion into cancer patients as soon as the decision to treat with cell therapy is made. It should also be cheaper to manufacture an allogenic cell therapy compared to an autologous one.

The deal between Sangamo and Gilead covers 10 or more products and includes a $150 million up-front payment to Sangamo and up to $3.01 billion in potential milestone payments. Like most drug-company partnerships, the milestones weren't spelled out, but the companies noted that the milestones are tied to successfully reaching certain research, development, regulatory, and commercialization events. Sangamo also gets undisclosed tiered royalties on products that result from the collaboration. Gilead is covering all the expenses for development, manufacturing, and commercialization of the products and will reimburse Sangamo for its agreed-upon expenses.

Now what

This is a good deal for Sangamo and certainly worthy of today's jump in the stock price. The $150 million will help pad its coffers to fund its internal pipeline of hemophilia and other treatments. It's hard to put a value on the large milestone payment, but presumably at least some of that $3 billion will flow through to Sangamo eventually.

The endorsement of Sangamo's technology by Gilead should also give investors some comfort, although considering that Sangamo has already done deals with such big names as Pfizer, the backing by Gilead is really just icing on the cake.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sangamo Therapeutics Stock Quote
Sangamo Therapeutics
$4.31 (-1.37%) $0.06
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.08 (0.80%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.